A Note from Tracy Valorie on
VYZULTA (latanoprostene bunod ophthalmic solution) 0.024%

August 21, 2018

Dear Eye Care Professional:

It’s been approximately eight months since we began making VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%, the only FDA approved nitric oxide releasing prostaglandin analog, available to you and your patients. We are encouraged by the positive initial feedback we’ve received on the performance of the product and continue to work to enhance our offerings for patients with open-angle glaucoma or ocular hypertension who may benefit from this treatment option. Please see Important Safety Information below.

In doing so, we are pleased to now offer a 2.5 mL bottle size in addition to our 5 mL bottle size of VYZULTA. This bottle size will allow you to provide a new one-month supply option to help your patients reduce their intraocular pressure (IOP).

In addition to offering more sizing options for the product, we also continue to make progress in working towards our goal of making VYZULTA affordable and accessible for your patients.

In March, we signed an agreement with Express Scripts, which covers VYZULTA under an access position on both the commercial Express Scripts National Preferred and Basic formularies, giving access to an additional 23 million patients in the United States.

Today most of your eligible commercially insured and eligible uninsured patients can utilize our copay assistance program, which is available on the VYZULTA website. This program is designed for those qualified patients who do not have commercial insurance coverage or who are without any insurance coverage and otherwise may be unable to afford treatment.

While we continue to work diligently to secure Medicare Part D coverage for 2019 and expand access for the almost 103 million patients who are insured through commercial, Medicare health insurers and pharmacy benefit managers (PBMs), you can help your patients obtain access to VYZULTA by submitting an electronic Prior Authorization (ePA) form or requesting coverage for a non-formulary product through the CoverMyMeds program. CoverMyMeds is designed to help eligible patients receive the medications they need by simplifying the ePA process for prescribers and pharmacists. The program also uncovers more potentially lost or rejected prescriptions, helping to get them into the hands of patients who need them.

VYZULTA is also included in the CoverMyMeds’ HubExpress platform, which manages through these ePA requests for product coverage made to health insurers and PBMs. If your request is approved, HubExpress will follow-up with the pharmacy to ensure the script is dispensed to the patient, and if denied, HubExpress will start an appeal or identify another course of action. For more information on the CoverMyMeds program, please reach out to your Bausch + Lomb sales representative or call 1-866-452-5017.

We truly appreciate your dedication and passion to ophthalmology, and it is our pleasure to be your trusted healthcare provider. Should you ever have any feedback, questions or ideas, please do not hesitate to contact me or the Bausch + Lomb team.

Best Regards,

Tracy Valorie

Senior Vice President and General Manager, U.S. Pharmaceuticals and Surgical
Bausch + Lomb

VYZULTA, dosed once daily, is thought to reduce IOP through two distinct pathways, the uveoscleral pathway and the trabecular meshwork pathway.1 In glaucoma patients, damage to the trabecular meshwork, through which the majority of the aqueous humor passes, can lead to reduced drainage and as a result elevated IOP. Lowering IOP, even in patients with normal baseline levels, can delay, or even prevent damage to optic nerves, helping to reduce the risk of glaucomatous visual field loss. In studies up to 12 months’ duration, the IOP-lowering effect was up to 7.5 to 9.1 mmHg for VYZULTA, in patients with an average baseline IOP of 26.7 mmHg.1 VYZULTA also has a Phase 2 dose ranging study vs. XALATAN (latanoprost) 0.005%. To learn more, visit https://www.vyzulta.com/hcp/clinical-studies.

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)


Click here for full Prescribing Information.


  1. VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% prescribing information. Bridgewater, NJ: Bausch & Lomb Incorporated; 2016.
  2. Weinreb RN, Ong T, Scassellati SB, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. June 2015;99(6):738-745.